Insider tradingForm 4
Definium Therapeutics, Inc. (DFTX) Insider Trading
6 open-market trades reported since Sep 4, 2026: 0 purchases worth $0 and 6 sales worth $3.02M.
By insider
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Robert Barrow | CEO | 0 | $0 | 2 | $1.88M |
| Mark Sullivan | General Counsel | 0 | $0 | 1 | $514K |
| Daniel Karlin | Chief Medical Officer | 0 | $0 | 1 | $397K |
| Brandi Roberts | CFO | 0 | $0 | 1 | $123K |
| Matthew T. Wiley | Chief Commercial Officer | 0 | $0 | 1 | $113K |
All trades
| Filed | Insider | Type | Value | 3 mo. after |
|---|---|---|---|---|
| Sep 29 | Robert BarrowCEO | ▼ SELL10b5-1 | $1.15M | |
| Sep 29 | Mark SullivanGeneral Counsel | ▼ SELL10b5-1 | $514K | |
| Sep 29 | Daniel KarlinChief Medical Officer | ▼ SELL10b5-1 | $397K | |
| Sep 29 | Brandi RobertsCFO | ▼ SELL10b5-1 | $123K | |
| Sep 29 | Matthew T. WileyChief Commercial Officer | ▼ SELL10b5-1 | $113K | |
| Sep 4 | Robert BarrowCEO | ▼ SELL10b5-1 | $722K |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings